Jovita Mezquita-Pla

Dr. Jovita Mezquita-Pla


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 1999 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JMJovita Mezquita-Pla
Jovita Mezquita-Pla
BMBetlem Mezquita
Betlem Mezquita
MPMontserrat Pau
Montserrat Pau
CMCristobal Mezquita
Cristobal Mezquita

14 February 2014 in Cells
Verified
Journal Article
Open access
PDF file
BMBetlem Mezquita
Betlem Mezquita
PMPau Mezquita
Pau Mezquita
MPMontserrat Pau
Montserrat Pau
JMJovita Mezquita-Pla
Jovita Mezquita-Pla
CMCristobal Mezquita
Cristobal Mezquita
One of the best examples of the renaissance of Src as an open door to cancer has been the demonstration that just five min of Src activation is sufficient for transformation and also for induction and maintenance of cancer stem cells [1]. Many tyrosine kinase receptors, through the binding of their ligands, become the keys that unlock the structure of Src and activate its oncogenic transduction pathways. Furthermore, intracellular isoforms of these receptors, devoid of any tyrosine kinase activity, still retain the ability to unlock Src. This has been shown with a truncated isoform of KIT (tr-KIT) and a truncated isoform of VEGFR-1 (i21-VEGFR-1), which are intracellular and require no ligand binding, but are nonetheless able to activate Src and induce cell migration and invasion of cancer cells. Expression of the i21-VEGFR-1 is upregulated by the Notch signaling pathway and repressed by miR-200c and retinoic acid in breast cancer cells. Both Notch inhibitors and retinoic acid have been proposed as potential therapies for invasive breast cancer.

7 March 2011 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
LWLi Wen
Li Wen
EGElizabeth A. Green
Elizabeth A. Green
TSThomas Stratmann
Thomas Stratmann
APAnaïs Panosa
Anaïs Panosa
RGRamon Gomis
Ramon Gomis
CMConchi Mora
Conchi Mora
CD4+ T lymphocytes are required to induce spontaneous autoimmune diabetes in the NOD mouse. Since pancreatic β cells upregulate Fas expression upon exposure to pro‐inflammatory cytokines, we studied whether the diabetogenic action of CD4+ T lymphocytes depends on Fas expression on target cells. We assayed the diabetogenic capacity of NOD spleen CD4+ T lymphocytes when adoptively transferred into a NOD mouse model combining: (i) Fas‐deficiency, (ii) FasL‐deficiency, and (iii) SCID mutation. We found that CD4+ T lymphocytes require Fas expression in the recipients' target cells to induce diabetes. IL‐1β has been described as a key cytokine involved in Fas upregulation on mouse β cells. We addressed whether CD4+ T cells require IL‐1β to induce diabetes. We also studied spontaneous diabetes onset in NOD/IL‐1 converting enzyme‐deficient mice, in NOD/IL‐1β‐deficient mice, and CD4+ T‐cell adoptively transferred diabetes into NOD/SCID IL‐1β‐deficient mice. Neither IL‐1β nor IL‐18 are required for either spontaneous or CD4+ T‐cell adoptively transferred diabetes. We conclude that CD4+ T‐cell‐mediated β‐cell damage in autoimmune diabetes depends on Fas expression, but not on IL‐1β unveiling the existing redundancy regarding the cytokines involved in Fas upregulation on NOD β cells in vivo.